BRPI0409865A - injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia - Google Patents

injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia

Info

Publication number
BRPI0409865A
BRPI0409865A BRPI0409865-0A BRPI0409865A BRPI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A
Authority
BR
Brazil
Prior art keywords
intravenous injection
plasminogen activators
neurotoxic plasminogen
neurotoxic
stroke attack
Prior art date
Application number
BRPI0409865-0A
Other languages
English (en)
Inventor
Mariola S Hngen
Wolfgang S Hngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of BRPI0409865A publication Critical patent/BRPI0409865A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"INJEçãO INTRAVENOSA DE ATIVADORES DE PLASMINOGêNIO NãO NEUROTóXICOS PARA O TRATAMENTO DO ATAQUE DE APOPLEXIA". A invenção refere-se à aplicação de fatores ativadores de plasminogênio não neurotóxicos, por exemplo, de Desmodus rotundus (DSPA) ou de fatores ativadores de plasminogênio geneticamente modificados, especialmente de origem humana para a preparação de um terápico injetável para o tratamento terapêutico do ataque de apoplexia no homem.
BRPI0409865-0A 2003-05-02 2004-04-30 injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia BRPI0409865A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/04608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
BRPI0409865A true BRPI0409865A (pt) 2006-05-16

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409865-0A BRPI0409865A (pt) 2003-05-02 2004-04-30 injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia

Country Status (10)

Country Link
EP (1) EP1622639B1 (pt)
JP (1) JP2006525270A (pt)
KR (1) KR101212631B1 (pt)
BR (1) BRPI0409865A (pt)
CA (1) CA2524573A1 (pt)
HR (1) HRP20050903B1 (pt)
NO (1) NO337485B1 (pt)
NZ (1) NZ543367A (pt)
PL (1) PL1622639T3 (pt)
WO (1) WO2004096268A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
JP2010524855A (ja) 2007-04-13 2010-07-22 ディフュージョン・ファーマシューティカルズ・エルエルシー 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用
ES2847293T3 (es) 2009-06-10 2021-08-02 Nono Inc Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
AU2010263245A1 (en) 2009-06-22 2012-01-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
DK3427748T3 (da) * 2011-06-24 2022-04-19 Nono Inc Kombinationsterapi mod iskæmi
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
KR102489034B1 (ko) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
NO20055692L (no) 2006-01-30
KR101212631B1 (ko) 2012-12-14
WO2004096268A2 (de) 2004-11-11
KR20060020616A (ko) 2006-03-06
HRP20050903A2 (en) 2006-08-31
WO2004096268A3 (de) 2005-04-21
NO337485B1 (no) 2016-04-25
NZ543367A (en) 2010-06-25
EP1622639B1 (de) 2013-01-16
EP1622639A2 (de) 2006-02-08
PL1622639T3 (pl) 2013-06-28
NO20055692D0 (no) 2005-12-01
CA2524573A1 (en) 2004-11-11
HRP20050903B1 (hr) 2013-11-22
JP2006525270A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
BRPI0409865A (pt) injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
EA200801570A1 (ru) Стабильные белковые препараты
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
BR9906813A (pt) Método para administração de insulina aspb28- humana
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
HK1064304A1 (en) Hdl for the treatment of stroke and other ischemicconditions
BR0308537A (pt) Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
ATE433959T1 (de) Analoge von kokain
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2007110709A8 (en) Formulations of tipifarnib for intravenous administration
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
ATE554793T1 (de) Konjugat
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S. (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25E Requested change of name of applicant rejected

Owner name: H. LUNDBECK A/S. (DK)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]